This summer, the Khasraw Lab will be hosting two undergraduate students as part of the Brain and Biological Sciences SURF program and the Duke-PRIME Cancer Research Program. Laura (left) is a rising sophomore at Duke University, who is interested in understanding the molecular mechanisms behind cancer development, with hopes to pursue research as a career. […]
May 9, 2025 The article describes our lab’s clinical trial, GIANT, which seeks to evaluate a novel neoadjuvant immunotherapy approach for glioblastoma, one of the most lethal brain cancers. The study will test a combination of nivolumab and relatlimab, immune checkpoint inhibitors previously used for melanoma, to see if they can improve outcomes when administered […]
June 6, 2024 This article describes the MOAB trial — studying the immunotherapy drug atezolizumab in patients with glioblastoma to determine if it can help them live longer and whether it boosts immune responses against tumors. The trial also investigates tumor mutational burden (TMB) to identify which patients might respond best to the drug, with […]
February 18, 2021 This New York Times article highlights how the pandemic significantly disrupted clinical trials, leading to the suspension or termination of thousands of studies due to safety concerns and logistical challenges. In response, many researchers adapted by implementing remote monitoring, telehealth consultations, and home delivery of medications. Dr. Khasraw was featured and emphasized […]
March 19, 2025 This article highlights how one reason for limited progress in glioblastoma treatment in recent years is the lack of understanding of tumor behavior at the proteomic and spatial levels. Integrated proteogenomic characterization—combining genomics, transcriptomics, and proteomics—has emerged as a promising approach to identify patient-specific molecular signatures. These insights can be used to […]
Lab member, Eugene Vaios, was awarded a competitive, year-long stipend for his methylation work titled Leveraging Cell-Free DNA Methylation Patterns to Develop a Non-Invasive Diagnostic and Surveillance Platform for Patients with Brain Tumors. Congratulations, Eugene!
Monday, April 21st, 4-6pm French Family Science Center